Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The 26-kDa protein encoded by the bcl-2 gene is a regulator of cell survival and blocks cell death induced by numerous stimuli. Amyloid beta protein (ABP) and glutamate are believed to play important roles in the neuronal cell death that occurs in
Alzheimer's disease
and stroke, respectively. Glutamate induces apoptosis in some neuronal cell systems, but it remains controversial whether ABP-mediated cell death occurs through apoptosis or necrosis. To further explore the pathways for cell death that are activated by these neurotoxins, we examined the effects of elevated levels of the p26-Bcl-2 protein on the susceptibility of neuronal cell lines to killing by glutamate and ABP. Gene transfer methods were used to elevate p26-Bcl-2 protein levels in the rat nerve lines PC-12 and B50 and the human
neuroblastoma
IMR-5. Bcl-2 protected all 3 cell lines from glutamate induced cell death but had no effect on killing mediated by ABP.
...
PMID:BCL-2 prevents killing of neuronal cells by glutamate but not by amyloid beta protein. 790 32
A phosphorylated tau epitope specific for paired helical filaments in
Alzheimer's disease
is recognized by monoclonal antibody PHF-1. Healthy adult brains lack the PHF-1 epitope (PHF-1 tau), but it is transiently expressed by immature neurons during development. We have found that proliferating SH-SY5Y human
neuroblastoma
cells also express PHF-1 tau. Consistent with the recent finding that cell-cycle-dependent kinases can phosphorylate tau in vitro, flow cytometry showed that mitotic SH-SY5Y cells were up to 18-fold more PHF-1 immunoreactive than nonmitotic cells. On immunoblots, PHF-1 tau in mitotic and nonmitotic cells also was strikingly different. First, mitosis induced a prominent PHF-1 reactive band at 120 kDa, which likely accounted for the large increase in PHF-1 signal seen at mitosis. Although the size of the 120-kDa band is consistent with it being the high-molecular-weight form of tau, other antibodies to tau did not recognize it. Second, mitosis caused a hyperphosphorylation of the PHF-1 immunoreactive tau band normally seen at 50 kDa. In mitotic cells this band had an increased intensity and molecular weight. Alkaline phosphatase treatment abolished tau M(r) heterogeneity, verifying that the variations in mobility were due to phosphorylation. These data show that cell-cycle-dependent hyperphosphorylation of tau occurs in intact cells, and they support the hypothesis that aberrant activity of cell-cycle-dependent kinases may contribute to tau phosphorylation and PHF formation in
Alzheimer's disease
.
...
PMID:Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human neuroblastoma cell line SH-SY5Y. 792 19
The
neuroblastoma
cell line NB-1 is induced to start neurite outgrowth by dibutyryl cyclic AMP (Bt2cAMP). To study the function of
Alzheimer
amyloid protein precursor (APP), a stable cell line overexpressing APP was established by cDNA transfection. The APP cDNA was driven by the cytomegalovirus early gene promoter. The transformant underwent degeneration as well as neurite outgrowth in the presence of Bt2cAMP, which also increased the amount of APP mRNA and protein. The expressed APP was mainly processed in the secretory pathway and few amyloidogenic fragments were observed. Hence, not only the beta/A4 protein but also the overexpressed APP itself might be neurotoxic.
...
PMID:The toxic effect of Alzheimer amyloid protein precursor overexpressed in the neuroblastoma cell line NB-1 on neurite outgrowth. 792 67
The effect of ciliary neurotrophic factor (CNTF) on beta-amyloid precursor protein (APP) gene expression was investigated in cultured rat C6 glioma cells and human SH-SY5Y
neuroblastoma
cells. CNTF increased APP mRNA abundance in C6 glioma cells in a dose-dependent manner, with an approximately 3-fold increase in maximum observed after 24 h with a concentration of 1 ng/ml. However, no significant differences in the splicing pattern of the three major isoforms of APP mRNA were apparent between control and CNTF-treated C6 glioma cells. CNTF had no effect on APP mRNA abundance in SH-SY5Y
neuroblastoma
cells. These findings suggest that CNTF can modulate APP mRNA expression and might affect amyloidogenesis in
Alzheimer's disease
.
...
PMID:Ciliary neurotrophic factor induced-increase in beta-amyloid precursor protein mRNA in rat C6 glioma cells. 794 86
Accumulation of an abnormal, protease-resistant form of an endogenous protein, PrP, is a characteristic feature of scrapie and related transmissible spongiform encephalopathies. This abnormal isoform is also present in the amyloid plaques that are often observed in these diseases. In mouse
neuroblastoma
cells persistently infected with scrapie, the abnormal protease-resistant isoform of PrP is derived from an operationally normal protease-sensitive precursor. Conversion of PrP to the protease-resistant state occurs either on the plasma membrane or along an endocytic pathway by an unknown mechanism. Inhibitors of protease-resistant PrP accumulation have been identified, and these include the amyloid-binding dye Congo red and certain sulfated glycans. The similarity of these compounds to sulfated glycosaminoglycans, which are components of all natural amyloids, has led to the hypothesis that the inhibitors act by competitively blocking an interaction between endogenous glycosaminoglycan(s) and PrP that is critical for amyloidogenic PrP accumulation. The proven prophylactic effect of these sulfated glycans in animal models of scrapie suggests that they represent a group of compounds that might interfere with the pathogenic formation of amyloid in a variety of diseases, such as
Alzheimer's disease
.
...
PMID:Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis. 799 7
The characteristic features of
Alzheimer's disease
(AD) include a high density of beta-amyloid-containing plaques in the cerebral cortex and the loss of basal forebrain cholinergic neurons. Amyloid beta-protein (A beta, Mr. approximately 4.5 kDa) is derived from a family of large (Mr. approximately 110-140 kDa) beta-amyloid precursor proteins (APP) which are integral membrane glycoproteins consisting of a large extracytoplasmic domain, a transmembrane domain, and a short cytoplasmic tail. Secreted derivatives of APP lacking the cytoplasmic tail, transmembrane domain, and a small portion of the extracellular domain are generated by the proteolytic processing of full length APP by a family of proteolytic enzymes known as APP secretases. Using cell cultures, we investigated the possibility that APP processing can be regulated by a centrally active cholinesterase inhibitor, tacrine, which has recently been shown to improve memory and cognitive functions in patients with AD. We analyzed the level of APP in glial, fibroblast, pheochromocytoma (PC12), and
neuroblastoma
cells by immunoblotting cell lysates and conditioned media. Normal levels of secretion of soluble APP derivatives by cells into conditioned media were severely inhibited by treating cells with tacrine. A similar decrease after treatment with tacrine was observed when
neuroblastoma
and PC12 cells were pretreated with either growth factors, phorbol ester, or retinoic acid. To determine whether the effect of tacrine on APP levels was specific or a more general phenomenon affecting other proteins, we measured the level of heat shock protein-70 (HSP-70) and another secretory protein, protease nexin-1 (PN-1). Tacrine treatment did not alter the level of HSP-70 in cell extracts and tacrine affected mildly the secretion of PN-1. Thus, the processing of HSP and PN-1, unlike APP, was not severely affected by treating cells with tacrine. Our results suggest that tacrine may inhibit an acetylcholinesterase-associated proteolytic activity involved in the secretion of APP, which results in less secretion of soluble APP into the conditioned media from tacrine treated cells. These results demonstrate that tacrine regulates APP secretion in cell cultures and suggest the possibility that tacrine therapy of
Alzheimer's disease
may, in the longer term, have effects on the process of A beta deposition.
...
PMID:Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. 804 78
The stability of proteins that constitute the neurofibrillary tangles and senile plaques of
Alzheimer disease
suggests that they would be ideal substrates for nonenzymatic glycation, a process that occurs over long times, even at normal levels of glucose, ultimately resulting in the formation of advanced glycation end products (AGEs). AGE-modified proteins aggregate, and they generate reactive oxygen intermediates. Using monospecific antibody to AGEs, we have colocalized these AGEs with paired helical filament tau in neurofibrillary tangles in sporadic
Alzheimer disease
. Such neurons also exhibited evidence of oxidant stress: induction of malondialdehyde epitopes and heme oxygenase 1 antigen. AGE-recombinant tau generated reactive oxygen intermediates and, when introduced into the cytoplasm of SH-SY5Y
neuroblastoma
cells, induced oxidant stress. We propose that in
Alzheimer disease
, AGEs in paired helical filament tau can induce oxidant stress, thereby promoting neuronal dysfunction.
...
PMID:Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. 805 61
It is important to apply an appropriate test for determining cell viability, in order to properly evaluate the role of the amyloid beta protein in neuronal degeneration in
Alzheimer's disease
. In the current paper, we present evidence that the putative neurotoxic fragment 25-35 of amyloid beta causes loss of trypan blue exclusion in differentiated mouse
neuroblastoma
N1E-115 cells which suggests a potential neurotoxic effect. Surprisingly, no parallel changes in apparent cell viability were observed when fluorescein diacetate staining or release of lactate dehydrogenase were measured. Positive staining with trypan blue was also induced by incubating cell membranes prepared from N1E-115 cells or rat hippocampus with amyloid beta 25-35. Our results indicate that amyloid beta might induce trypan blue adsorption on the cell membrane. Therefore, caution should be taken when trypan blue exclusion is used in studies of the potential neurotoxicity of amyloid beta peptides.
...
PMID:An artifact associated with using trypan blue exclusion to measure effects of amyloid beta on neuron viability. 808 5
Normal processing of the amyloid beta protein precursor (beta APP) results in secretion of a soluble 4-kilodalton protein essentially identical to the amyloid beta protein (A beta) that forms insoluble fibrillar deposits in
Alzheimer's disease
. Human
neuroblastoma
(M17) cells transfected with constructs expressing wild-type beta APP or the beta APP717 mutants linked to familial
Alzheimer's disease
were compared by (i) isolation of metabolically labeled 4-kilodalton A beta from conditioned medium, digestion with cyanogen bromide, and analysis of the carboxyl-terminal peptides released, or (ii) analysis of the A beta in conditioned medium with sandwich enzyme-linked immunosorbent assays that discriminate A beta 1-40 from the longer A beta 1-42. Both methods demonstrated that the 4-kilodalton A beta released from wild-type beta APP is primarily but not exclusively A beta 1-40. The beta APP717 mutations, which are located three residues carboxyl to A beta 43, consistently caused a 1.5- to 1.9-fold increase in the percentage of longer A beta generated. Long A beta (for example, A beta 1-42) forms insoluble amyloid fibrils more rapidly than A beta 1-40. Thus, the beta APP717 mutants may cause
Alzheimer's disease
because they secrete increased amounts of long A beta, thereby fostering amyloid deposition.
...
PMID:An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. 819 Dec 90
Activation of the complement system is believed to be involved in degenerative processes of certain neurological diseases, including
Alzheimer disease
. Recent data have shown that the mRNAs for these proteins can be detected in brain-derived mRNA. In this study, C4 mRNA was detected by polymerase chain reaction (PCR) amplification of mRNA from the human
neuroblastoma
cell lines IMR32, SK-SH and SK-MC, and the human astrocytoma cell line U373MG, while C3 expression was detected in SK-MC, SK-SH and U373MG cells. The SK-MC and U373MG cells expressed mRNA for C9. The mRNA for C1qB could not be detected in any of these cell lines.
...
PMID:Complement gene expression in neuroblastoma and astrocytoma cell lines of human origin. 823 40
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>